RBN013209
Product Specifications
UNSPSC Description
RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors[1][2][3].
Target Antigen
CD38; LAG-3; PD-1/PD-L1; Tim3
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/rbn013209.html
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
COCCO[C@@H](CC1)CC[C@H]1NC(C2=C3C(C=CN3)=NC(N4C=CN=C4)=N2)=O
Molecular Weight
384.43
References & Citations
[1]Laurie B. Schenkel, et al. Heterobicyclic amides as inhibitors of cd38. WO2021021986A1.|[2]Shambharkar, et al. Small molecule inhibitor of CD38 modulates its intra-and extracellular functions leading to antitumor activity. Cancer Research 81.13_Supplement (2021): 1344-1344.|[3]Huang Y, et al. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell Rep Med. 2024 Feb 20;5(2):101400.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-144987/RBN013209-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-144987/RBN013209-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
2597933-17-8
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
